NEW YORK (GenomeWeb) – German cancer diagnostics firm New Oncology today announced the closing of a €5 million ($5.7 million) financing round.

New Oncology offers the next-generation sequencing-based NEO platform for molecular analysis of genetic mutations in patient samples to help clinicians select targeted therapies and identify potential clinical trial opportunities. The technology identifies mutations, gene fusions, amplifications, and indels for which there are approved drugs or experimental substances in clinical testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.